Among 5-year survivors in the tebentafusp arm, 44% received tebentafusp as their only therapy. In contrast, 86% of control ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results